The scientist’s investigation covers issues in Internal medicine, Surgery, Transplantation, Oncology and Immunology. His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. His Surgery research integrates issues from Risk factor and Lymphoma.
As a part of the same scientific family, David C. Linch mostly works in the field of Transplantation, focusing on Fludarabine and, on occasion, Donor lymphocyte infusion. His Oncology study combines topics in areas such as Odds ratio, Cyclophosphamide, Non-Hodgkin's lymphoma, Case-control study and Autologous stem-cell transplantation. He interconnects Myelopoiesis, Survival analysis and Stem cell in the investigation of issues within Immunology.
His primary scientific interests are in Internal medicine, Immunology, Surgery, Oncology and Transplantation. David C. Linch combines topics linked to Gastroenterology with his work on Internal medicine. The study incorporates disciplines such as CD34 and Cancer research in addition to Immunology.
His work is dedicated to discovering how Surgery, Rituximab are connected with Diffuse large B-cell lymphoma and other disciplines. The various areas that David C. Linch examines in his Oncology study include Myeloid leukemia, NPM1 and Minimal residual disease. His Transplantation research includes elements of Stem cell and Fludarabine.
His primary areas of investigation include Internal medicine, Oncology, Cancer research, Rituximab and Diffuse large B-cell lymphoma. His Internal medicine research includes themes of Gastroenterology, Surgery and Immunology. His research integrates issues of Haematopoiesis and Incidence in his study of Immunology.
The Oncology study combines topics in areas such as Myeloid leukemia, NPM1, Univariate analysis, Genotype and Concomitant. David C. Linch combines subjects such as T cell, Mutant, Fludarabine, CD19 and Chronic lymphocytic leukemia with his study of Cancer research. His Rituximab study integrates concerns from other disciplines, such as Extranodal Disease, Follicular lymphoma and Chemotherapy regimen.
Internal medicine, Leukemia, Myeloid, Cancer research and Immunology are his primary areas of study. His biological study spans a wide range of topics, including Oncology and Genotype. His studies in Leukemia integrate themes in fields like Wnt signaling pathway, DNA methylation, Molecular biology, Myeloid leukemia and Regulation of gene expression.
His study in Cancer research is interdisciplinary in nature, drawing from both Protein kinase B, Phosphoinositide 3-kinase, Cell growth, Mutation and Minimal residual disease. He works mostly in the field of Immunology, limiting it down to topics relating to Cumulative incidence and, in certain cases, Performance status, Survival analysis and Concomitant, as a part of the same area of interest. His Rituximab research is multidisciplinary, incorporating elements of B-cell lymphoma and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Panagiotis D. Kottaridis;Rosemary E. Gale;Marion E. Frew;Georgina Harrison.
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani;Edward G.D. Tuddenham;Savita Rangarajan;Cecilia Rosales.
The New England Journal of Medicine (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht;Bertram Glass;Nicolas Mounier;Devinder Singh Gill.
Journal of Clinical Oncology (2010)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial
D C Linch;D Winfield;A H Goldstone;D Moir.
The Lancet (1993)
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Steven J. Howe;Marc R. Mansour;Kerstin Schwarzwaelder;Cynthia Bartholomae.
Journal of Clinical Investigation (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale;Claire Green;Christopher Allen;Adam J. Mead.
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
N Schmitz;P Dreger;D.C Linch;A.H Goldstone.
The Lancet (1996)
Assessment of Minimal Residual Disease in Standard-Risk AML.
Adam Ivey;Robert Kerrin Hills;Michael A. Simpson;Jelena V. Jovanovic.
The New England Journal of Medicine (2016)
Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at Treatment
A J Swerdlow;J A Barber;G V Hudson;D Cunningham.
Journal of Clinical Oncology (2000)
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: